TSE:4568Pharmaceuticals
How Investors Are Reacting To Daiichi Sankyo Company (TSE:4568) New Real-World Bempedoic Acid Cardiovascular Data
Daiichi Sankyo recently reported new real-world data from the multinational MILOS study at the European Society of Cardiology 2026 Congress in Munich, showing that bempedoic acid, alone or with ezetimibe, produced clinically relevant LDL-C reductions and estimated 10-year cardiovascular risk reductions in dyslipidaemia patients.
The findings highlight that bempedoic acid-based regimens delivered consistent LDL-C lowering and risk estimates across sexes and glycaemic profiles, reinforcing its...